BioMarin's Rare Disease Portfolio Expands with Pending Inozyme Pharma Takeover

Rhea-AI Filing Summary

Inozyme Pharma has announced the postponement of its 2025 Annual Meeting of Stockholders, originally scheduled for June 25, 2025, due to a pending acquisition by BioMarin Pharmaceutical. If the acquisition completes, no public stockholder annual meeting will be held. If it doesn't proceed, the Board will reschedule the meeting with a new record date.

Key Company Profile:

• Clinical-stage biopharmaceutical company with ~50 Boston-based employees
• Focuses on PPi-Adenosine Pathway therapeutics for bone health and blood vessel function
• Lead therapy INZ-701, an ENPP1 Fc fusion protein, is in late-stage clinical trials
• Target conditions include ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis

The filing includes detailed information about the tender offer process and directs stockholders to review important acquisition-related documents filed with the SEC by both companies. Materials are available on the SEC website and both companies' respective websites.

Insights

Corporate Governance Specialist

Inozyme postponed its annual meeting due to pending acquisition by BioMarin; no meeting needed if deal closes.

This filing reveals Inozyme Pharma has postponed its 2025 Annual Meeting of Stockholders that was scheduled for June 25, 2025. The postponement is directly linked to the company's pending acquisition by BioMarin Pharmaceutical. The filing explicitly states that if the acquisition completes, there will be no Annual Meeting involving public stockholders - a clear indication that the transaction is expected to result in Inozyme becoming a wholly-owned subsidiary of BioMarin.

The postponement decision signals that the acquisition is progressing and likely nearing completion. For current shareholders, this procedural move eliminates the need to participate in governance matters that would soon become irrelevant post-acquisition. Should the acquisition not complete, Inozyme's Board would reconvene the Annual Meeting at a later date with a new record date for voting eligibility.

This postponement is a standard governance procedure during pending acquisitions and represents the company's pragmatic approach to avoid unnecessary administrative processes. The filing also reiterates background information about Inozyme as a clinical-stage biopharmaceutical company with approximately 50 employees focused on therapies targeting the PPi-Adenosine Pathway, particularly its lead candidate INZ-701 for ENPP1 Deficiency.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

 

 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

 

☐ Preliminary Proxy Statement

 

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

☐ Definitive Proxy Statement

 

☒ Definitive Additional Materials

 

☐ Soliciting Material Pursuant to § 240.14a-12

INOZYME PHARMA, INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

 

☒ No fee required

 

☐ Fee paid previously with preliminary materials

 

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

On June 20, 2025, Inozyme Pharma, Inc. (“Inozyme” or the “Company”) issued the following press release in connection with Inozyme’s 2025 Annual Meeting of Stockholders:

Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

BOSTON, Mass, June 20, 2025 – Inozyme Pharma, Inc. (Nasdaq: INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), which was scheduled to be held on June 25, 2025, in light of the previously announced acquisition (the “Acquisition”) by BioMarin Pharmaceutical Inc. (“BioMarin”).

If the Acquisition is completed, there will be no Annual Meeting involving public stockholders. If the Acquisition is not completed, the Board of Directors will take such further action as it deems appropriate to call and convene the Annual Meeting at a later date, including the establishment of a new record date for determining the stockholders entitled to vote at the Annual Meeting.

About Inozyme

Inozyme Pharma is a clinical-stage biopharmaceutical company, with approximately 50 employees based in Boston. The company is dedicated to developing innovative therapeutics that target the PPi-Adenosine Pathway, a key regulator of bone health and blood vessel function. Disruptions in this pathway underlie a range of severe diseases, including ENPP1 Deficiency. Our lead investigational therapy, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy designed to restore pyrophosphate and adenosine levels. INZ-701 is currently in late-stage clinical development in ENPP1 Deficiency, with the potential to expand into additional indications where deficiencies in the Pyrophosphate-Adenosine Pathway contribute to disease pathology, including ABCC6 Deficiency and calciphylaxis. Through our pioneering work, we aim to transform treatment options for patients affected by these devastating conditions.

To learn more, please visit www.inozyme.com.

Investor Relations Contact:

Inozyme Pharma

Stefan Riley, Senior Director of IR and Corporate Communications

(617) 461-2442

Stefan.riley@inozyme.com

Additional Information About the Acquisition and Where to Find It

This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that Inozyme, BioMarin or its acquisition subsidiary has filed with the SEC. The solicitation and offer to tender and the offer to buy outstanding shares of Inozyme will only be made pursuant to a tender offer statement on Schedule TO, including an Offer to Purchase and related tender offer materials that BioMarin and its acquisition subsidiary, Incline Merger Sub, Inc., has filed with the SEC. At the time the tender offer commenced, BioMarin and its acquisition subsidiary filed a Tender Offer Statement on Schedule TO, and Inozyme filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS), AS WELL AS THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9, CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF INOZYME ARE URGED TO READ THESE DOCUMENTS CAREFULLY (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS OF INOZYME SHOULD CONSIDER BEFORE MAKING ANY DECISION WITH RESPECT TO THE TENDER OFFER. The tender offer materials (including the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents), as well as the Solicitation/Recommendation Statement, are available to all investors and stockholders of Inozyme at no expense to them at SEC’s website at www.sec.gov. Copies of the documents filed with the SEC by BioMarin will be available free of charge on

BioMarin’s website at www.biomarin.com. Copies of the documents filed with the SEC by Inozyme will be available free of charge on Inozyme’s website, www.inozyme.com, or by contacting Inozyme’s investor relations department at investorrelations@inozyme.com. The information contained in, or that can be accessed through, BioMarin’s and Inozyme’s websites is not a part of, or incorporated by reference herein. In addition to the Offer to Purchase, related Letter of Transmittal and certain other tender offer documents, and Solicitation/Recommendation Statement, BioMarin and Inozyme file annual, quarterly, and current reports, proxy statements and other information with the SEC. You may read any reports, statements or other information filed by BioMarin and Inozyme with the SEC for free on the SEC’s website at www.sec.gov.

FAQ

Why did INZY postpone its 2025 Annual Meeting of Stockholders?

INZY postponed its 2025 Annual Meeting of Stockholders, originally scheduled for June 25, 2025, due to the previously announced acquisition by BioMarin Pharmaceutical Inc. (BioMarin). If the acquisition is completed, there will be no Annual Meeting involving public stockholders.

What happens to INZY's Annual Meeting if the BioMarin acquisition fails?

If the BioMarin acquisition is not completed, INZY's Board of Directors will take appropriate action to call and convene the Annual Meeting at a later date, including establishing a new record date for determining stockholders entitled to vote at the Annual Meeting.

What is INZY's main product and therapeutic focus?

INZY's lead investigational therapy is INZ-701, an ENPP1 Fc fusion protein enzyme replacement therapy designed to restore pyrophosphate and adenosine levels. The company focuses on the PPi-Adenosine Pathway, targeting conditions like ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis.

How many employees does INZY have and where is it based?

Inozyme Pharma is based in Boston and has approximately 50 employees. The company operates as a clinical-stage biopharmaceutical company focused on developing innovative therapeutics.

Where can INZY shareholders find information about the BioMarin tender offer?

INZY shareholders can access tender offer materials through the SEC's website at www.sec.gov, BioMarin's website (www.biomarin.com), or Inozyme's website (www.inozyme.com). Key documents include the Tender Offer Statement on Schedule TO, Offer to Purchase, Letter of Transmittal, and Solicitation/Recommendation Statement on Schedule 14D-9.